Du är här

2018-10-15

Karolinska Development AB (publ): Karolinska Development's portfolio company Pharmanest changes name and signs licensing ag...

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company
Phamanest changes its name to Palette Life Sciences. The company also
announces a global licensing agreement with Nestlé Skin Health.

Palette Life Sciences (former Pharmanest) has announced a licensing agreement
with Nestlé Skin Health. The agreement gives Palette Life Sciences the
worldwide commercialization and development rights for three products:
Deflux®, Solesta® and BarrigelTM.

The products are all based on the NASHATM(Non Animal Stabilized Hyaluronic
Acid) technology. Palette Life Sciences will focus immediately on sales of
Deflux and Solesta and will begin preparing for worldwide commercialization
of Barrigel. Nestlé Skin Health will continue to manufacture the products on
behalf of Palette Life Sciences.

Palette Life Science will continue the development of SHACT under the name
LidbreeTM. Lidbree will be submitted for European regulatory review later
this year.

Karolinska Development is a passive investor in Palette Life Sciences and
maintains an ownership of 10,4 per cent in the company.

For more details please visit:
www.pharmanest.se

www.palettelifesciences.com

For further information, please contact :

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make
a difference to patients' lives while providing an attractive return on
investment to shareholders.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes
in the Nordic region. The Company aims to build companies around scientists
who are leaders in their fields, supported by experienced management teams
and advisers, and co-funded by specialist international investors, to provide
the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with
a proven track record as company builders and with access to a strong global
network.

For more information, please visitwww.karolinskadevelopment.com

KD Press release Palette Life Sciences October 2018
http://hugin.info/143071/R/2220547/868857.pdf

---------------------------------------
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.